MA39986A - Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer - Google Patents
Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancerInfo
- Publication number
- MA39986A MA39986A MA039986A MA39986A MA39986A MA 39986 A MA39986 A MA 39986A MA 039986 A MA039986 A MA 039986A MA 39986 A MA39986 A MA 39986A MA 39986 A MA39986 A MA 39986A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- cancer
- treatment
- purine derivatives
- purine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Abstract
La présente invention concerne de nouveaux composés, leurs sels pharmaceutiquement acceptables, et leurs compositions pharmaceutiques, qui sont des inhibiteurs de cd73 et sont utiles dans le traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984659P | 2014-04-25 | 2014-04-25 | |
US201462051529P | 2014-09-17 | 2014-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39986A true MA39986A (fr) | 2017-03-01 |
Family
ID=53175630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039986A MA39986A (fr) | 2014-04-25 | 2015-04-23 | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer |
Country Status (5)
Country | Link |
---|---|
US (1) | US10654884B2 (fr) |
EP (1) | EP3134411B1 (fr) |
JP (1) | JP6657182B2 (fr) |
MA (1) | MA39986A (fr) |
WO (1) | WO2015164573A1 (fr) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10167302B2 (en) * | 2014-05-23 | 2019-01-01 | University College Cork | Phosphonate nucleosides useful in the treatment of viral diseases |
EA038349B1 (ru) | 2014-11-21 | 2021-08-12 | Бристол-Маерс Сквибб Компани | Антитела, содержащие модифицированные константные участки тяжелой цепи |
EP3725808A1 (fr) | 2014-11-21 | 2020-10-21 | Bristol-Myers Squibb Company | Anticorps anti-cd73 et leurs utilisations |
TW202227095A (zh) | 2016-01-08 | 2022-07-16 | 美商阿克思生物科學有限公司 | 胞外5'-核苷酸酶之調節劑及其用途 |
AU2017316965B2 (en) * | 2016-08-26 | 2020-09-10 | Mitsubishi Tanabe Pharma Corporation | Bicyclic nitrogenated heterocyclic compound |
US10472364B2 (en) | 2016-09-09 | 2019-11-12 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
CN110049767B (zh) * | 2016-10-03 | 2023-04-04 | 艾库斯生物科学有限公司 | 腺苷5′-核苷酸酶的抑制剂 |
US11267845B2 (en) | 2016-11-18 | 2022-03-08 | Arcus Biosciences, Inc. | Inhibitors of CD73-mediated immunosuppression |
CN110402249A (zh) * | 2016-12-22 | 2019-11-01 | 卡利泰拉生物科技公司 | 外核苷酸酶抑制剂及其使用方法 |
US11578136B2 (en) | 2017-03-16 | 2023-02-14 | Innate Pharma | Compositions and methods for treating cancer |
EP3600273A4 (fr) * | 2017-03-31 | 2021-01-20 | Peloton Therapeutics, Inc. | Inhibiteurs de cd73 et leurs utilisations |
KR101841604B1 (ko) | 2017-04-26 | 2018-03-26 | 순천대학교 산학협력단 | 퍼푸린을 유효성분으로 포함하는 우울증 및 불안증의 예방 또는 치료용 조성물 |
US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
EA039042B1 (ru) * | 2017-09-08 | 2021-11-25 | Калитера Байосайенсиз, Инк. | Ингибиторы эктонуклеотидазы и способы их применения |
CA3074588A1 (fr) | 2017-10-06 | 2019-04-11 | Innate Pharma | Restauration de l'activite de lymphocytes t par l'axe cd39/cd73 |
US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
CN111867628A (zh) | 2018-03-09 | 2020-10-30 | 东莞凡恩世生物医药有限公司 | 抗cd73抗体及其用途 |
US20200405629A1 (en) * | 2018-03-09 | 2020-12-31 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
MX2020011542A (es) | 2018-04-30 | 2020-11-24 | Oric Pharmaceuticals Inc | Inhibidores de cd73. |
EP3810109A4 (fr) | 2018-05-31 | 2022-03-16 | Peloton Therapeutics, Inc. | Compositions et procédés d'inhibition de cd73 |
EP3807316A1 (fr) | 2018-06-18 | 2021-04-21 | Innate Pharma | Compositions et méthodes pour le traitement du cancer |
EP3810617A4 (fr) * | 2018-06-21 | 2022-06-29 | Calithera Biosciences, Inc. | Inhibiteurs d'ectonucléotidases et leurs procédés d'utilisation |
EP3843742A4 (fr) * | 2018-08-28 | 2022-04-20 | Jiangsu Hengrui Medicine Co., Ltd. | Inhibiteurs de cd73 et leurs utilisations thérapeutiques |
US11530234B2 (en) | 2018-09-11 | 2022-12-20 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
EP3849992A4 (fr) | 2018-09-11 | 2022-06-29 | Risen (Suzhou) Pharma Tech Co., Ltd. | Inhibiteurs de cd73 et utilisations pharmaceutiques associées |
CN111184698A (zh) * | 2018-11-15 | 2020-05-22 | 和记黄埔医药(上海)有限公司 | 呋喹替尼制剂及其应用 |
US11819512B2 (en) | 2018-12-13 | 2023-11-21 | Arcus Biosciences, Inc. | Solid forms of a CD73 inhibitor and the use thereof |
CN112955444B (zh) * | 2019-01-22 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
WO2020190073A1 (fr) * | 2019-03-20 | 2020-09-24 | 한국화학연구원 | Composition pharmaceutique comprenant un nouveau composé hétérocyclique azolopyrimidine en tant que principe actif |
WO2020205538A1 (fr) * | 2019-03-29 | 2020-10-08 | Eternity Bioscience Inc. | Inhibiteurs de cd73 et leurs utilisations thérapeutiques |
WO2020210938A1 (fr) * | 2019-04-15 | 2020-10-22 | Bioardis Llc | Dérivés de quinazoline en tant qu'inhibiteurs de cd73 |
EP3986894A4 (fr) * | 2019-06-20 | 2023-08-09 | Antengene Therapeutics Limited | Inhibiteurs d'ectonucléotidases et leurs procédés d'utilisation |
US20220331343A1 (en) * | 2019-07-16 | 2022-10-20 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
EP4041393A1 (fr) | 2019-10-09 | 2022-08-17 | Bayer Aktiengesellschaft | Nouveaux composés hétéroaryle-triazole utilisés comme pesticides |
IL292570B2 (en) | 2019-10-30 | 2024-04-01 | Oric Pharmaceuticals Inc | CD73 inhibitors |
US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
WO2021247188A1 (fr) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Essai d'activité biologique antagoniste de cd73 et procédés d'utilisation de celui-ci |
CN115942977A (zh) | 2020-06-17 | 2023-04-07 | 艾库斯生物科学有限公司 | Cd73抑制剂的结晶形式及其用途 |
CN113549076B (zh) * | 2021-07-23 | 2022-12-06 | 中国药科大学 | 一种多取代嘌呤类化合物及其制备方法和应用 |
WO2023201267A1 (fr) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Polythérapie pour le traitement de cancers exprimant trop-2 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69943308D1 (de) | 1998-07-01 | 2011-05-05 | Univ Pennsylvania | Hohlraum-induzierte allosterische Modifikation von intermolekularen Interaktionen und Verfahren zur Identifikation von Verbindungen, die diese bewirken |
US20040043959A1 (en) * | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
WO2006130217A2 (fr) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Esters de phosphate de phosphonates de nucleosides substitues |
EP1860113A1 (fr) * | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Inhibiteurs d'ectonucléosidase |
US8956824B2 (en) | 2006-12-04 | 2015-02-17 | British Columbia Cancer Agency Branch | Methods for identifying allosteric modulators of ship polypeptides |
US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
US8865653B2 (en) | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
WO2012031320A1 (fr) | 2010-09-06 | 2012-03-15 | Peter Maccallum Cancer Institute | Diagnostic du cancer |
WO2014153424A1 (fr) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Réduction de diabète chez des patients recevant des inhibiteurs de l'hmg-coa réductase (statines) |
-
2015
- 2015-04-23 WO PCT/US2015/027235 patent/WO2015164573A1/fr active Application Filing
- 2015-04-23 MA MA039986A patent/MA39986A/fr unknown
- 2015-04-23 EP EP15722317.3A patent/EP3134411B1/fr active Active
- 2015-04-23 US US15/306,197 patent/US10654884B2/en active Active
- 2015-04-23 JP JP2017507914A patent/JP6657182B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20170044203A1 (en) | 2017-02-16 |
US10654884B2 (en) | 2020-05-19 |
WO2015164573A1 (fr) | 2015-10-29 |
JP6657182B2 (ja) | 2020-03-04 |
EP3134411B1 (fr) | 2021-06-30 |
EP3134411A1 (fr) | 2017-03-01 |
JP2017513955A (ja) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
PH12016501972B1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
HK1243999A1 (zh) | 新型3-吲哚取代的衍生物、藥物組合物及使用方法 | |
MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
WO2016044556A3 (fr) | Inhibiteurs d'arginine méthyltransférase et leurs utilisations | |
MY176235A (en) | Compounds that inhibit mcl-1 protein | |
PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
IL261015A (en) | History of methylamine as lysis oxidase inhibitors for cancer treatment | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
TW201613864A (en) | Novel compounds | |
MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
PH12016501997A1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
HK1251476A1 (zh) | 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽 | |
MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. | |
MX2017002747A (es) | Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak. | |
PH12017501063A1 (en) | Compounds for the treatment of cancer |